PRX-03140

PRX-03140
Clinical data
ATC code	None;
Identifiers
	IUPAC name 4-hydroxy-7-isopropyl-6-oxo-N-[3-(1-piperidinyl)propyl]-6,7-dihydrothieno[2,3-b]pyridine-5-carboxamide;
CAS Number	869493-21-0;
PubChem CID	54677674;
ChemSpider	21377738;
UNII	7QGN8QXG7I;
CompTox Dashboard (EPA)	DTXSID90236013 ;
Chemical and physical data
Formula	C19H27N3O3S
Molar mass	377.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N1C(=O)\C(=C(\O)c2ccsc12)C(=O)NCCCN3CCCCC3;
	InChI InChI=1S/C19H27N3O3S/c1-13(2)22-18(25)15(16(23)14-7-12-26-19(14)22)17(24)20-8-6-11-21-9-4-3-5-10-21/h7,12-13,23H,3-6,8-11H2,1-2H3,(H,20,24); Key:SCHKZZSVELPJKU-UHFFFAOYSA-N;

PRX-03140 is a partial agonist (18% relative to 5-HT^[1]) of the 5-HT₄ receptor that was developed by EPIX Pharmaceuticals for Alzheimer's disease.^[2]

Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts. In 2009, Epix was in the process of asset liquidation due to insufficient funds to stay afloat. Nanotherapeutics, Inc. acquired the product in 2010 conducting one clinical study in PTSD patients. In 2018 the product was transferred to Nanoshift, LLC. Nanoshift LLC and Nanopharmaceutics, Inc. (www.nanopharmaceutics.com) continue to support clinical studies. It has been tested in six Phase 1 and Phase 2 clinical trials.

References

↑ Shen F, Smith JA, Chang R, et al. (2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515. S2CID 43281377.
↑ Shen, F (August 2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515. S2CID 43281377.

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid21392515-1] Shen F, Smith JA, Chang R, et al. (2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515. S2CID 43281377.

[Shen-2] Shen, F (August 2011). "5-HT(4) receptor agonist mediated enhancement of cognitive function in vivo and amyloid precursor protein processing in vitro: A pharmacodynamic and pharmacokinetic assessment". Neuropharmacology. 61 (1–2): 69–79. doi:10.1016/j.neuropharm.2011.02.026. PMID 21392515. S2CID 43281377.

[1]

[2]